Autres langues NeuroBo Pharmaceuticals, Inc.

Actions

NRBO

US64132R4048

Temps réel estimé Cboe BZX Autres places de cotation 21:44:28 03/06/2024			Varia. 5j.	Varia. 1 janv.
4,015 ^USD	+5,38 %		-4,08 %	+8,21 %

22/05	NeuroBo Pharmaceuticals, Inc. annonce des données précliniques sur le DA-1241, un nouvel agoniste du récepteur 119 couplé à la protéine G (GPR119), en combinaison avec le Semaglutide	CI
09/05	NeuroBo Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

NeuroBo Pharmaceuticals, Inc. Announces Pre-Clinical Data of DA-1241, a Novel G-Protein-Coupled Receptor 119 Agonist, in Combination with Semaglutide	22/05
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
NEUROBO PHARMACEUTICALS, INC. : Maxim toujours à l'achat	08/05
NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity	17/04
NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash	01/04
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
NeuroBo Pharmaceuticals to Continue Trial of Liver Disease Treatment Candidate -- Shares Down	13/03
NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash	13/03
NeuroBo Pharmaceuticals Names Marshall Woodworth Finance Chief	04/03
NeuroBo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity	29/02
US Equity Markets Close Higher Thursday Following Jobless Claims Data	01/02
Sector Update: Health Care Stocks Rise in Late Afternoon	01/02
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading	01/02
Top Midday Gainers	01/02
NeuroBo Gets FDA Clearance For DA-1726 Trial in Obesity; Shares Soar	01/02
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment	01/02
Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2A Clinical Trial Evaluating Da-1241 for the Treatment of Mash	18/01
NeuroBo Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Price Rule	09/01
NeuroBo Pharmaceuticals Submits New Drug Application to FDA for Phase 1 Trial of DA-1726 for Obesity; Shares Rise	28/12
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity	28/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues NeuroBo Pharmaceuticals, Inc.

Actions

NRBO

US64132R4048

Autres langues

Filtres